Summit Therapeutics (SMMT) Posts Earnings Results, Misses Expectations By $0.34 EPS

Retrieved on: 2018-04-10 22:26:15

Tags for this article:

Economy

Financial analyst

Securities research

Summit Therapeutics

Click the tags to see associated articles and topics

Summit Therapeutics (SMMT) Posts Earnings Results, Misses Expectations By $0.34 EPS. View article details on hiswai:

Excerpt

<div>Susquehanna International Group LLP purchased a new stake in Summit Therapeutics in the 3rd quarter worth about $1,828,000. <b>Acadian Asset</b> <b>Management</b> LLC grew its holdings in Summit Therapeutics by 192.8% during the 4th quarter. <b>Acadian Asset Management</b> LLC now owns 144,083 shares of ...</div>

Article found on:

View Original Article